Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease Meeting Abstract

  

Authors:	Markova, A.; Prockop, S. E.; Dusza, S.; Pan, A.; Chowdhury, A.; Lacouture, M. E.; Perales, M. A.; Ponce, D. M.
Abstract Title:	Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
Meeting Title:	2022 Tandem Meetings of ASTCT and CIBMTR
Journal Title:	Transplantation and Cellular Therapy
Volume:	28
Issue:	3 Suppl.
Meeting Dates:	2022 Apr 23-26
Meeting Location:	Salt Lake City, UT
ISSN:	2666-6375
Publisher:	Elsevier Inc.
Date Published:	2022-03-01
Start Page:	S302
End Page:	S303
Language:	English
DOI:	10.1016/S2666-6367(22)00550-4
PROVIDER:	manual
Notes:	Meeting Abstract: 390 -- Located within the section named "Poster Session - Graft-Versus-Host And Graft-Versus-Tumor - Clinical Prevention, Treatment And Biomarkers"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/196991